FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 214 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused... December 11, 2023 El cáncer en mi comunidad: El rol de la detección del... November 5, 2020 BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions May 18, 2020 Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded... April 5, 2023 Load more HOT NEWS 2021 ASCO Annual Meeting: New Treatments and Research Advances in Esophageal... Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk... For People with Inherited Risk of Stomach Cancer, Gastrectomy Has Lasting... Happy 29th Birthday OncoLink!
